Journal Article

Half-life extension using serum albumin-binding DARPin® domains

Daniel Steiner, Frieder W Merz, Ivo Sonderegger, Maya Gulotti-Georgieva, Denis Villemagne, Douglas J Phillips, Patrik Forrer, Michael T Stumpp, Christof Zitt and H Kaspar Binz

in Protein Engineering, Design and Selection

Volume 30, issue 9, pages 583-591
Published in print September 2017 | ISSN: 1741-0126
Published online August 2017 | e-ISSN: 1741-0134 | DOI:
Half-life extension using serum albumin-binding DARPin® domains

Show Summary Details



A long systemic half-life is key for therapeutic proteins. To that end we have generated serum albumin-binding designed ankyrin repeat domains. These domains bind serum albumin of different species with nanomolar affinities, and have significantly improved pharmacokinetic properties both in mouse and cynomolgus monkey compared to non-serum albumin-binding DARPin® domains. In addition, they exhibit high thermal stability and long storage stability, which is an essential feature for their use in drug development. Covalently linking a serum albumin-binding DARPin® domain to domains with other target specificities results in improvements of multiple orders of magnitude in exposure and terminal half-life, both in mouse and cynomolgus monkey. Pharmacokinetic assessment of such constructs revealed terminal half-life values ranging from 27 h to 80 h in mouse, and from 2.6 days to 20 days in cynomolgus monkey. Extrapolation by allometric scaling on these findings suggests terminal half-life values of 5–50 days in human, indicating that pharmacokinetic properties in the range of monoclonal antibodies can be achieved with DARPin® drug candidates. Such serum albumin-binding DARPin® domains are thus valuable tools for the generation of multi-functional drugs with an extended in vivo half-life.

Keywords: designed ankyrin repeat protein; half-life; pharmacokinetics; serum albumin

Journal Article.  6436 words.  Illustrated.

Subjects: Proteins

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.